Skin squamous cell carcinoma

This early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…

This early-stage study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 150 adults with certain…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early pilot study tested a new radioactive bandage called CivaDerm on 10 people with common skin cancers (basal cell or squamous cell carcinoma). The bandage delivers radiation directly to the skin surface, aiming to destroy cancer cells while sparing healthy tissue. The stu…

This phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…

This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent skin cancer from returning in people with high-risk locally advanced squamous cell carcinoma who had already undergone surgery and radiation. About 450 participants were randomly assigned…

This study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had returned or spread. The goal was to see if the combination could shrink tumors or slow the disease. Participants were grouped based on whether they …

This early study tested a drug called cemiplimab, which helps the immune system attack cancer cells. The drug was injected directly into skin tumors (squamous cell or basal cell carcinoma) for 3 to 12 weeks before planned surgery. The main goal was to check safety and find the ri…

This study looked at kidney transplant patients who already had one skin cancer. It compared switching their anti-rejection medicine to rapamycin versus staying on standard drugs. The goal was to see if rapamycin could prevent new skin cancers over two years while keeping the tra…

This study tested giving the drug cemiplimab before surgery to people with advanced skin cancer (stage II to IV). The goal was to see if the drug could shrink or eliminate the tumor before the operation. 79 adults took part. The main focus was on how many patients had no cancer c…

This phase 2 trial tested a combination of a short, intense course of radiation (quad-shot) and the immunotherapy drug pembrolizumab in 21 people with advanced, recurrent, or metastatic head and neck cancer. The goal was to see if the combination could shrink tumors and be safe. …

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This study tracked 287 people with advanced skin cancer (squamous cell or basal cell) to see how well the drug cemiplimab works outside of a clinical trial. Researchers measured tumor shrinkage, survival, and side effects. The goal was to understand real-world effectiveness and s…

This early-phase trial tested two doses of the drug erlotinib (Tarceva) given before surgery in 48 people with head and neck cancer. The goal was to see how the drug affects a protein called phospho-Akt in tumor samples. Researchers hope erlotinib might slow tumor growth by block…

This early-phase study tested an investigational drug called CLR 131, which delivers radiation directly to tumor cells, combined with standard external beam radiation. It enrolled 12 people with head and neck cancer that had returned after prior treatment. The main goal was to ch…

This trial tests whether indocyanine green, a dye injected before surgery, can find sentinel lymph nodes as reliably as the standard technetium-99 radioactive tracer. About 744 adults with various cancers will receive both agents, and surgeons will compare detection rates using a…

This phase 2 trial tested whether adding venlafaxine (an antidepressant) to a standard pain regimen of gabapentin, methadone, and oxycodone could better control pain in 62 people with head and neck cancer undergoing chemoradiation. The study measured pain scores and side effects …

Researchers are examining skin cancer among people whose jobs involve long hours in the sun. The study uses national administrative and medical records to describe who develops these cancers, including age, sex, region, cancer type, and disability outcomes. The goal is to underst…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This study examined 119 people with precancerous or early skin cancer lesions to understand how cells change as they become cancerous. Researchers took small skin samples and analyzed their metabolism and protein markers. The goal was to learn more about the transition from harml…

This study looked at how 78 patients with high-risk skin cancer on the head or neck felt about their treatment decisions, quality of life, and satisfaction with care. Researchers used standard questionnaires to measure these factors at two points: right after a team of doctors di…

This study looked at whether certain vitamin D receptor gene variations are linked to non-melanoma skin cancer risk in an Alabama population. Researchers compared 200 people aged 50 and older, some with skin cancer and some without, by analyzing their DNA from blood samples. The …